322 related articles for article (PubMed ID: 36734633)
21. Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice.
Wang W; Qin JJ; Voruganti S; Wang MH; Sharma H; Patil S; Zhou J; Wang H; Mukhopadhyay D; Buolamwini JK; Zhang R
Gastroenterology; 2014 Oct; 147(4):893-902.e2. PubMed ID: 25016295
[TBL] [Abstract][Full Text] [Related]
22. MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53.
Klein AM; Biderman L; Tong D; Alaghebandan B; Plumber SA; Mueller HS; van Vlimmeren A; Katz C; Prives C
Proc Natl Acad Sci U S A; 2021 Nov; 118(44):. PubMed ID: 34716260
[TBL] [Abstract][Full Text] [Related]
23. An MDM2 degrader for treatment of acute leukemias.
Marcellino BK; Yang X; Ümit Kaniskan H; Brady C; Chen H; Chen K; Qiu X; Clementelli C; Herschbein L; Li Z; Elghaity-Beckley S; Arandela J; Kelly B; Hoffman R; Liu J; Xiong Y; Jin J; Shih AH
Leukemia; 2023 Feb; 37(2):370-378. PubMed ID: 36309559
[TBL] [Abstract][Full Text] [Related]
24. Development of selective small molecule MDM2 degraders based on nutlin.
Wang B; Wu S; Liu J; Yang K; Xie H; Tang W
Eur J Med Chem; 2019 Aug; 176():476-491. PubMed ID: 31128449
[TBL] [Abstract][Full Text] [Related]
25. COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells.
Synnott NC; O'Connell D; Crown J; Duffy MJ
Breast Cancer Res Treat; 2020 Jan; 179(1):47-56. PubMed ID: 31538264
[TBL] [Abstract][Full Text] [Related]
26. Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders.
Yang J; Li Y; Aguilar A; Liu Z; Yang CY; Wang S
J Med Chem; 2019 Nov; 62(21):9471-9487. PubMed ID: 31560543
[TBL] [Abstract][Full Text] [Related]
27. p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer.
Tentler JJ; Ionkina AA; Tan AC; Newton TP; Pitts TM; Glogowska MJ; Kabos P; Sartorius CA; Sullivan KD; Espinosa JM; Eckhardt SG; Diamond JR
Mol Cancer Ther; 2015 May; 14(5):1117-29. PubMed ID: 25758253
[TBL] [Abstract][Full Text] [Related]
28. MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53.
Hines J; Lartigue S; Dong H; Qian Y; Crews CM
Cancer Res; 2019 Jan; 79(1):251-262. PubMed ID: 30385614
[TBL] [Abstract][Full Text] [Related]
29. Dual targeting of MDM2 with a novel small-molecule inhibitor overcomes TRAIL resistance in cancer.
Singh AK; Chauhan SS; Singh SK; Verma VV; Singh A; Arya RK; Maheshwari S; Akhtar MS; Sarkar J; Rangnekar VM; Chauhan PMS; Datta D
Carcinogenesis; 2016 Nov; 37(11):1027-1040. PubMed ID: 27543608
[TBL] [Abstract][Full Text] [Related]
30. Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.
Zhang S; Zhou L; Hong B; van den Heuvel AP; Prabhu VV; Warfel NA; Kline CL; Dicker DT; Kopelovich L; El-Deiry WS
Cancer Res; 2015 Sep; 75(18):3842-52. PubMed ID: 26294215
[TBL] [Abstract][Full Text] [Related]
31. Ablation of Cancer Stem Cells by Therapeutic Inhibition of the MDM2-p53 Interaction in Mucoepidermoid Carcinoma.
Andrews A; Warner K; Rodriguez-Ramirez C; Pearson AT; Nör F; Zhang Z; Kerk S; Kulkarni A; Helman JI; Brenner JC; Wicha MS; Wang S; Nör JE
Clin Cancer Res; 2019 Mar; 25(5):1588-1600. PubMed ID: 30498096
[TBL] [Abstract][Full Text] [Related]
32. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
Xiong J; Yang Q; Li J; Zhou S
Angiogenesis; 2014 Jan; 17(1):37-50. PubMed ID: 23907365
[TBL] [Abstract][Full Text] [Related]
33. Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer.
Jabbour-Leung NA; Chen X; Bui T; Jiang Y; Yang D; Vijayaraghavan S; McArthur MJ; Hunt KK; Keyomarsi K
Mol Cancer Ther; 2016 Apr; 15(4):593-607. PubMed ID: 26826118
[TBL] [Abstract][Full Text] [Related]
34. Chemical degrader enhances the treatment of androgen receptor-positive triple-negative breast cancer.
Wu Y; Xue J; Li J
Arch Biochem Biophys; 2022 May; 721():109194. PubMed ID: 35337811
[TBL] [Abstract][Full Text] [Related]
35. Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.
Synnott NC; Bauer MR; Madden S; Murray A; Klinger R; O'Donovan N; O'Connor D; Gallagher WM; Crown J; Fersht AR; Duffy MJ
Cancer Lett; 2018 Feb; 414():99-106. PubMed ID: 29069577
[TBL] [Abstract][Full Text] [Related]
36. Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction.
Soares J; Pereira NA; Monteiro Â; Leão M; Bessa C; Dos Santos DJ; Raimundo L; Queiroz G; Bisio A; Inga A; Pereira C; Santos MM; Saraiva L
Eur J Pharm Sci; 2015 Jan; 66():138-47. PubMed ID: 25312347
[TBL] [Abstract][Full Text] [Related]
37. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
38. Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.
Krishnan SR; Nair BC; Sareddy GR; Roy SS; Natarajan M; Suzuki T; Peng Y; Raj G; Vadlamudi RK
Breast Cancer Res Treat; 2015 Apr; 150(3):487-99. PubMed ID: 25788226
[TBL] [Abstract][Full Text] [Related]
39. The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy.
Liu Y; Wang X; Wang G; Yang Y; Yuan Y; Ouyang L
Eur J Med Chem; 2019 Aug; 176():92-104. PubMed ID: 31100649
[TBL] [Abstract][Full Text] [Related]
40. Hypomethylation-Linked Activation of PLCE1 Impedes Autophagy and Promotes Tumorigenesis through MDM2-Mediated Ubiquitination and Destabilization of p53.
Chen Y; Xin H; Peng H; Shi Q; Li M; Yu J; Tian Y; Han X; Chen X; Zheng Y; Li J; Yang Z; Yang L; Hu J; Huang X; Liu Z; Huang X; Zhou H; Cui X; Li F
Cancer Res; 2020 Jun; 80(11):2175-2189. PubMed ID: 32066565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
